SCHEMBL6489176

SCHEMBL6489176

CCOc1cnc(Cn2c(C)nc3c(C)cc(OCc4ccccc4C(=O)OC)cc32)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 6/20 0.38
MCL1 Q07820 6/20 0.38
MAPT P10636 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MEN1 O00255 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
DCTPP1 Q9H773 1/20 0.36
NPBWR1 P48145 1/20 0.36
THRB P10828 1/20 0.35
TP53 P04637 1/20 0.34
PLA2G2A P14555 1/20 0.33
OPRL1 P41146 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7169897 0.92 BCL2 (0.39) BCL2MCL1MAPTSMN1; SMN2MEN1
SCHEMBL6490992 0.92 BCL2 (0.45) BCL2MCL1HTTTP53PLA2G2A
SCHEMBL6488710 0.91 BCL2 (0.39) BCL2MCL1MAPTHTTDCTPP1
SCHEMBL6490267 0.90 BCL2 (0.38) BCL2MCL1MAPTSMN1; SMN2KMT2A
SCHEMBL6499279 0.89 BCL2 (0.38) BCL2MCL1MAPTKMT2ADCTPP1
SCHEMBL6499570 0.89 BCL2 (0.42) BCL2MCL1MAPTSMN1; SMN2MEN1
SCHEMBL6487299 0.88 MRGPRX4 (0.42) BCL2MCL1MAPTSMN1; SMN2MEN1
SCHEMBL6495279 0.86 MAPT (0.36) MAPTSMN1; SMN2CYP3A4CYP2C9CYP2C19
SCHEMBL6487607 0.85 REN (0.38) BCL2MCL1DCTPP1
SCHEMBL6489607 0.83 MEN1 (0.41) BCL2MCL1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD BCL2 774/4885MCL1 806/4885MAPT 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.